HKSE - Delayed Quote HKD

JUNSHI BIO (1877.HK)

Compare
11.540
-0.040
(-0.35%)
At close: February 7 at 4:08:07 PM GMT+8
Loading Chart for 1877.HK
DELL
  • Previous Close 11.580
  • Open 11.580
  • Bid 11.460 x --
  • Ask 11.540 x --
  • Day's Range 11.360 - 11.740
  • 52 Week Range 9.170 - 21.700
  • Volume 1,380,000
  • Avg. Volume 1,056,103
  • Market Cap (intraday) 24.831B
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) --
  • EPS (TTM) -2.110
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 15.52

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

www.junshipharma.com

2,568

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1877.HK

View More

Performance Overview: 1877.HK

Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

1877.HK
0.69%
HANG SENG INDEX
5.35%

1-Year Return

1877.HK
9.98%
HANG SENG INDEX
31.41%

3-Year Return

1877.HK
74.78%
HANG SENG INDEX
14.02%

5-Year Return

1877.HK
51.92%
HANG SENG INDEX
22.88%

Compare To: 1877.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1877.HK

View More

Valuation Measures

As of 2/7/2025
  • Market Cap

    24.89B

  • Enterprise Value

    24.09B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.56

  • Price/Book (mrq)

    1.63

  • Enterprise Value/Revenue

    13.90

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -100.90%

  • Return on Assets (ttm)

    -10.52%

  • Return on Equity (ttm)

    -26.94%

  • Revenue (ttm)

    1.79B

  • Net Income Avi to Common (ttm)

    -1.8B

  • Diluted EPS (ttm)

    -2.110

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.04B

  • Total Debt/Equity (mrq)

    44.20%

  • Levered Free Cash Flow (ttm)

    -1.58B

Research Analysis: 1877.HK

View More

People Also Watch